Pharming Group (ENXTAM:PHARM) - Aandelenkoers, Nieuws & Analyse

PHARM Overzicht aandelen

Pharming Group N.V., een biofarmaceutisch bedrijf, ontwikkelt en commercialiseert eiwitvervangingstherapieën en precisiemedicijnen voor de behandeling van zeldzame ziekten in de Verenigde Staten, Europa en internationaal.

Over het bedrijf

PHARM fundamentele analyse
Sneeuwvlok Score
Waardering	6/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 90.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 73.16% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Analisten zijn het erover eens dat de aandelenkoers met 143.9% zal stijgen

Risicoanalyse

Volatiele aandelenkoers in de afgelopen 3 maanden

Pharming Group N.V. Concurrenten

Galapagos

ENXTAM:GLPG

€1.7b

Tango Therapeutics

NasdaqGM:TNGX

US$347.1m

HLB TherapeuticsLtd

KOSDAQ:A115450

₩736.6b

Beijing Kawin Technology Share-Holding

SHSE:688687

CN¥4.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Pharming Group
Historische aandelenkoersen
Huidige aandelenkoers	€0.74
52 Week Hoogtepunt	€1.22
52 Week Laag	€0.65
Bèta	0.81
11 maand verandering	-4.34%
3 maanden verandering	2.50%
1 Jaar Verandering	-30.44%
33 jaar verandering	-7.38%
5 jaar verandering	-39.51%
Verandering sinds IPO	-99.22%

Recent nieuws en updates

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12

Rendement voor aandeelhouders

	PHARM	NL Biotechs	NL Markt
7D	-4.1%	1.2%	0.6%
1Y	-30.4%	7.6%	11.2%

Rendement versus industrie: PHARM presteerde slechter dan de Dutch Biotechs -sector, die het afgelopen jaar een rendement van 7.6 % opleverde.

Rendement versus markt: PHARM presteerde slechter dan Dutch Market, dat het afgelopen jaar een rendement van 11.2 % opleverde.

Prijsvolatiliteit

Is PHARM's price volatile compared to industry and market?
PHARM volatility
PHARM Average Weekly Movement	6.8%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.0%
10% most volatile stocks in NL Market	7.3%
10% least volatile stocks in NL Market	2.2%

Stabiele aandelenkoers: De aandelenkoers van PHARM is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van PHARM is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Dutch.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1988	382	Simon de Vries	www.pharming.com

Pharming Group N.V., een biofarmaceutisch bedrijf, ontwikkelt en commercialiseert eiwitvervangingstherapieën en precisiegeneesmiddelen voor de behandeling van zeldzame ziekten in de Verenigde Staten, Europa en internationaal. Het bedrijf biedt RUCONEST, een recombinante C1-esteraseremmer voor de behandeling van acute aanvallen bij volwassen en adolescente patiënten met acuut erfelijk angio-oedeem (HAE); en Joenja (leniolisib), een orale kleine molecule PI3K? remmer voor de behandeling van geactiveerd fosfoinositide 3-kinase delta syndroom.

Pharming Group N.V. Samenvatting

Hoe verhouden de winst en inkomsten van Pharming Group zich tot de beurswaarde?
PHARM fundamentele statistieken
Marktkapitalisatie	€513.85m
Inkomsten(TTM)	-€16.53m
Inkomsten(TTM)	€264.94m

1.9x

P/S-verhouding

-30.3x

Koers/Winstverhouding

Is PHARM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PHARM resultatenrekening (TTM)
Inkomsten	US$285.75m
Kosten van inkomsten	US$30.30m
Brutowinst	US$255.44m
Overige uitgaven	US$273.26m
Inkomsten	-US$17.82m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.026
Brutomarge	89.39%
Nettowinstmarge	-6.24%
Schuld/Eigen Vermogen Verhouding	42.3%

Hoe presteerde PHARM op de lange termijn?

Bekijk historische prestaties en vergelijking

PHARM Overzicht aandelen

Beloningen

Risicoanalyse

Pharming Group N.V. Concurrenten

ENXTAM:GLPG

€1.7b

NasdaqGM:TNGX

US$347.1m

KOSDAQ:A115450

₩736.6b

SHSE:688687

CN¥4.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Recent updates

Consensus estimates of losses per share improve by 14%

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

New minor risk - Share price stability

Price target decreased by 7.8% to €1.78

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Insufficient new directors

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Price target increased by 11% to €2.00

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Consensus estimates of losses per share improve by 31%

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Consensus EPS estimates upgraded to US$0.014 loss, revenue downgraded

Consensus estimates of losses per share improve by 34%

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 140%

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Price target increased by 8.9% to €1.83

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Now 20% undervalued

Now 20% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings: EPS exceeds analyst expectations

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Price target increased to €13.52

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations